Gilead Stops Six Trials Due to Adverse Events, Death
The six clinical trials in question involved small lymphocytic lymphoma, CLL, and indolent non-Hodgkin lymphoma (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 16, 2016 Category: Pharmaceuticals Source Type: news

ADC Therapeutics begins dosing in ADCT-402 Phase I trial for B-NHL patients
Swiss firm ADC Therapeutics (ADCT) has started a Phase I trial of its antibody drug conjugate (ADC) ADCT-402 in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - March 14, 2016 Category: Pharmaceuticals Source Type: news

Did an artificial football pitch cause this amateur player's death?
Ian Cole, from Basingstoke, Hampshire, died in 2012 of non-Hodgkin lymphoma, an illness which has caused the deaths of more than 100 footballers in America in recent years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 9, 2016 Category: Consumer Health News Source Type: news

Seattle Genetics begins Phase I trial of SGN-CD19B to treat non-Hodgkin lymphoma
Seattle Genetics has started a Phase I clinical trial of SGN-CD19B, a new antibody-drug conjugate (ADC) for relapsed or refractory patients with B-cell non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - February 26, 2016 Category: Pharmaceuticals Source Type: news

Medical News Today: Is height, weight linked to rise in non-Hodgkin's lymphoma?
Non-Hodgkin's lymphoma has been on the rise for the last 30 years. The reasons for this are unclear, but investigations into height and weight are yielding fresh clues. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2016 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Weight and height during adolescence may impact future risk of developing Non-Hodgkin's lymphoma
(Wiley) A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin's lymphoma, a type of cancer of the lymphatic system. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2016 Category: Cancer & Oncology Source Type: news

New Cancer Therapy Could Give Hope To 'Incurable' Patients
A new experimental treatment has achieved what chemotherapy and bone marrow transplants have failed to do: put chronic, relapsing blood cancers into remission. What's more, it uses the body's own natural defense system to attack these cancerous growths.  The treatment involves T cells, a type of immune cell that works as your body's own personal S.W.A.T. team to detect, surround, and destroy foreign invaders like bacteria or viruses. Historically, cancerous cells have grown too fast for T cells to mount an effective defense, and they can also trick T cells into thinking that they’re a healthy part of t...
Source: Science - The Huffington Post - February 17, 2016 Category: Science Source Type: news

FDA to Start Testing for Glyphosate in Food
This article originally appeared on Civil Eats (Source: TIME.com: Top Science and Health Stories)
Source: TIME.com: Top Science and Health Stories - February 17, 2016 Category: Consumer Health News Authors: Carey Gillam / CivilEats.com Tags: Uncategorized Cancer FDA Food glyphosate health Nutrition Pesticide public health Roundup Toxin toxins weed killer Source Type: news

Alzheimer's disease 'wonder drug' claims are premature
ConclusionThe number of people with Alzheimer's disease is increasing as the global population ages. Researchers have estimated 44 million people currently have the condition, and this number will grow to more than 135 million by 2050. It's believed the condition is caused at least in part by the accumulation of toxic aggregates of beta-amyloid protein pieces in the brain. Researchers hope stopping this aggregation could be a way to prevent or treat the disease, but have not yet found successful ways of doing this.This piece of research looked at nerve cells and microscopic worms genetically modified to develop beta-amyloi...
Source: NHS News Feed - February 15, 2016 Category: Consumer Health News Tags: Medication Neurology Older people Source Type: news

The Cancer Moonshot Could Depend Most on You
In his State of the Union address, President Barack Obama announced that Vice President Joe Biden would lead an effort toward a "moonshot" cure for cancer. More recently, Vice President Biden met with health care leaders at the World Economic Forum in Davos to build momentum for the initiative, and later will meet with agency officials and Cabinet members about how the federal government can fund more research and treatment. This is an ambitious task, to say the least, especially for a disease whose "cure" is often regarded as synonymous with an impossible dream. Cancer kills more than half a milli...
Source: Science - The Huffington Post - February 8, 2016 Category: Science Source Type: news

NICE consulting on non-Hodgkin's lymphoma guideline
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2016 Category: Drugs & Pharmacology Source Type: news

Valor begins dosing in Phase I trial of IGN002 to treat non-Hodgkin lymphoma
Valor Biotherapeutics (Valor) has started a Phase I clinical trial of its lead product candidate, IGN002, to treat patients with refractory and relapsed non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - January 11, 2016 Category: Pharmaceuticals Source Type: news

New data from pivotal study showed Roche’s Gazyva/Gazyvaro induced deep remissions and provided meaningful quality of life improvements in people with difficult-to-treat indolent non-Hodgkin lymphoma
Roche today announced follow-up results from the pivotal phase III GADOLIN study in people with indolent non-Hodgkin lymphoma (iNHL) who relapsed during or within six months after treatment with a MabThera®/Rituxan® (rituximab)-based regimen. (Source: Roche Media News)
Source: Roche Media News - December 7, 2015 Category: Pharmaceuticals Source Type: news

New data from pivotal study showed Roche’s Gazyva/Gazyvaro induced deep remissions and provided meaningful quality of life improvements in people with difficult-to-treat indolent non-Hodgkin lymphoma
Roche today announced follow-up results from the pivotal phase III GADOLIN study in people with indolent non-Hodgkin lymphoma (iNHL) who relapsed during or within six months after treatment with a MabThera®/Rituxan® (rituximab)-based regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2015 Category: Pharmaceuticals Source Type: news

Amgen and Merck Announce Cancer Immunotherapy Collaboration for Patients with Non-Hodgkin Lymphoma
Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Collaboration Includes Additional Select Advanced Solid Tumors THOUSAND OAKS, Calif. and KENILWORTH, N.J. – Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO...
Source: Merck - December 4, 2015 Category: Pharmaceuticals Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I am v...
Source: JEMS Administration and Leadership - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership General News History of EMS Provider Wellness & Safety Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I am v...
Source: JEMS Operations - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership General News History of EMS Provider Wellness & Safety Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I am v...
Source: JEMS Special Topics - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership General News History of EMS Provider Wellness & Safety Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I ...
Source: JEMS Special Topics - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership Source Type: news

Kidney failure and its treatment may impact cancer risk
Risk of kidney and thyroid cancers was especially high when kidney failure patients were on dialysis, researchers have discovered. Conversely, risk of non-Hodgkin lymphoma, melanoma, lung cancer, and certain skin cancers was highest following kidney transplantation, likely due to immunosuppressant medications. Kidney failure is on the rise and currently afflicts an estimated 2 million people worldwide. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 13, 2015 Category: Science Source Type: news

World first blood cancer drug trial reveals life-changing results
A breakthrough has been achieved with the results of the world-first clinical trial with actual patients of a new drug to treat particular blood cancers. This clinical trial, a first-in-human study, looked at the efficacy of a new inhibitor, ONO/GS-4059, in the treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma patients refractory or resistant to current chemotherapies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 11, 2015 Category: Science Source Type: news

PET/CT predicts stem cell transplant success in lymphoma
The presence of lesions on FDG-PET/CT scans prior to stem cell transplantation...Read more on AuntMinnie.comRelated Reading: SNMMI: PET/CT aids non-Hodgkin's lymphoma patients FDG-PET/CT tops biopsy in lymphoma patients FDG-PET/CT, MRI can help assess stem cell transplant response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 29, 2015 Category: Radiology Source Type: news

AdvaMed taps LifeScience Alley’s Mandle to lead state medtech alliance | Personnel Moves
AdvaMed said it named Shaye Mandle, CEO of Minnesota’s LifeScience Alley trade association, as chairman of its State Medical Technology Alliance. “The medical technology industry is a hallmark of U.S. innovation represented by a community of people dedicated to improving and saving lives. Now more than ever, medical technology has the opportunity to help deliver better and more affordable care to patients worldwide. The efforts of SMTA members are critical to providing our elected leaders with the information needed to ensure the full national and global impact of this vital industry,” Mandle said in prep...
Source: Mass Device - October 28, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Business/Financial News AdvaMed Direct Flow Medical Inc. Edwards Lifesciences Innfocus NeoChord Inc. Personnel Moves Prism Medical RTI Surgical SeaSpine Shape Memory Therapeutics VentriPoint Diagnostics Source Type: news

5 Reasons Why Running Is a Metaphor for Life
At the beginning of 2011--at 47 years of age--I took up running for two reasons. One: I had a problem controlling my weight (I wasn't huge, but I wasn't svelte either) and two: to honour my friend Dave Fitzsimons--a two time Olympian and champion runner--who died of non-Hodgkins lymphoma in 2008. In 2010, a 5 kilometre event--Fitzy's 5--was held in his honour, and I walked it, determined to run it the next year. When I first started running, I couldn't run 50 metres to save myself, even though I was an efficient walker. However, by the end of 2011--with my iPhone, a running app and a few start running classes--I could run ...
Source: Healthy Living - The Huffington Post - October 27, 2015 Category: Consumer Health News Source Type: news

Bacterium that causes Q fever linked to non-Hodgkin lymphoma
The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 13, 2015 Category: Science Source Type: news

Study: Bacterium that causes Q fever linked to non-Hodgkin lymphoma
(American Society of Hematology) The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2015 Category: Biology Source Type: news

Armed malaria protein found to kill cancer cells
(The Centre for Drug Research and Development) In models of non-Hodgkin's lymphoma, castration-resistant prostate cancer, and metastatic breast cancer, the Kairos-VAR2 therapeutic demonstrated the ability to prevent tumor growth, regress established tumors, and cure metastatic disease. The studies were published today in the journal Cancer Cell. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 13, 2015 Category: Cancer & Oncology Source Type: news

Rituximab-Related APF in Diffuse Large B-Cell LymphomaRituximab-Related APF in Diffuse Large B-Cell Lymphoma
This patient with diffuse large B-cell non-Hodgkin lymphoma developed pulmonary fibrosis after treatment with rituximab. Might an increase in TNF-alpha levels be implicated? American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 25, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Seattle's Immune Design teams up with Merck, stock soars
Seattle biotech company Immune Design (Nasdaq: IMDZ) announced a new partnership Monday that will help further the company's immunotherapy treatments. Immune Design has entered into a clinical collaboration with New Jersey-based pharmaceutical company Merck (NYSE: MRK) to evaluate the safety and efficacy of two of the Seattle company's immunotherapy products in Phase 1 clinical trails for patients with non-Hodgkin's lymphoma and melanoma. The trials will examine how each of those two products —… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 11, 2015 Category: American Health Authors: Annie Zak Source Type: news

Merck and Immune Design to assess two immunotherapies with Keytruda for NHL and Melanoma
Clinical-stage immunotherapy firm Immune Design has partnered with the subsidiaries of Merck to assess the safety and efficacy of its oncology investigative agents, G100 and LV305, with Merck's Keytruda (pembrolizumab) for non-Hodgkin's lymphoma (NHL… (Source: Drug Development Technology)
Source: Drug Development Technology - August 11, 2015 Category: Pharmaceuticals Source Type: news

Topical gel proves safe, effective treatment for patients with skin t cell lymphoma
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin. Currently, there is no cure for CTCL aside from a bone marrow transplant. However, the new study shows that the topical gel can eliminate malignant T cells, leading to diminished lesions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 6, 2015 Category: Science Source Type: news

Melanoma twice as likely after CLL/SLL than other types of NHL
Survivors of chronic lymphocytic leukemia/small lymphocytic lymphoma are twice as likely to develop melanoma as are survivors of other types of non-Hodgkin lymphoma, according to a report published online Aug. 3 in Journal of Clinical Oncology. Since patients with chronic lymphocytic...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 3, 2015 Category: Dermatology Source Type: news

Veterans Exposed To Toxic Chemicals Accuse VA Of Foot-Dragging
Retired Senior Master Sgt. Leslie Howe has battled two cancers -- non-Hodgkin lymphoma and prostate cancer, both of which have been linked with exposure to Agent Orange, the herbicide used by the U.S. military to destroy enemy cover and crops during the Vietnam War. Howe, 71, was never actually in Vietnam during the conflict, but in the 1980s he served aboard Air Force planes that contained trace amounts of the defoliant. Still, the U.S. Department of Veterans Affairs twice denied Howe's benefits claim, telling him in a letter that it "could not find a link" between his medical conditions and his military service...
Source: Science - The Huffington Post - July 21, 2015 Category: Science Source Type: news

Epizyme starts tazemetostat’s Phase II trial for non-Hodgkin lymphoma
Clinical-stage biopharmaceutical firm Epizyme has enrolled the first subject in its Phase II trial of clinical candidate, tazemetostat (EPZ-6438), in patients with relapsed or refractory non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2015 Category: Pharmaceuticals Source Type: news

Mayo Clinic receives $11 million grant from NCI to study cancer survivorship
(Mayo Clinic) Mayo Clinic announced today that it has received a five-year, $11 million grant from the National Cancer Institute to study survivorship in patients with non-Hodgkin lymphoma (NHL). The Lymphoma Epidemiology of Outcomes Cohort Study will enroll 12,000 patients with NHL. The study will follow these patients for long-term prognosis and survivorship. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2015 Category: Cancer & Oncology Source Type: news

Mayo Clinic Receives $11 Million Grant from National Cancer Institute to Study Cancer Survivorship
ROCHESTER, MINN. – Mayo Clinic announced today that it has received a five-year, $11 million grant from the National Cancer Institute (NCI) to study survivorship in patients with non-Hodgkin lymphoma (NHL). The Lymphoma Epidemiology of Outcomes Cohort Study will enroll 12,000 patients with NHL. The study will follow these patients for long-term prognosis and survivorship. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - July 8, 2015 Category: Research Source Type: news

Zimbabwe: Comedians Raise Funds for Cancer Patient
[The Herald] No contribution is too small for Takudzwa Paradza, who was diagnosed with a high degree of Non-Hodgkin's Lymphoma in September last year and has since gone through numerous chemotherapy sessions. Comedians across the nation have decided to join hands to help fund-raise the remaining $3 000 which the young man needs for treatment. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 1, 2015 Category: African Health Source Type: news

Non-Hodgkin Lymphoma Risk and Insecticide, Fungicide and Fumigant Use in the Agricultural Health Study
Reports on a study to determine any linkage between the agricultural use of specific pesticides and the occurrence of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) on agricultural workers. (Source: Rural publications via the Rural Assistance Center)
Source: Rural publications via the Rural Assistance Center - July 1, 2015 Category: Rural Health Source Type: news

Maryland Governor Larry Hogan, Patient-In-Chief
Larry Hogan’s victory in the Maryland 2014 gubernatorial race surprised everyone, a completely unanticipated Republican victory in one of the bluest of blue states. On Monday, Governor Hogan surprised us with another upset, this one far less welcome to his supporters. At a hastily convened press conference, the Governor announced that he has B-cell non-Hodgkin lymphoma, a cancer of the lymph nodes, advanced and “very aggressive.” He said he felt a golf-ball sized lump in his neck when he was shaving. A series of doctor visits and tests ultimately confirmed the troubling diagnosis. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 24, 2015 Category: Pharmaceuticals Authors: Leah Binder Source Type: news

Gov. Larry Hogan's Stage 3 Non-Hodgkin Lymphoma Diagnosis, Explained
Maryland Gov. Larry Hogan (R) announced on Monday that he has been diagnosed with late stage 3 non-Hodgkin lymphoma, an aggressive form of lymph node cancer. Hogan, 59, sought medical attention after noticing a lump in his neck while shaving, and his doctors discovered more than 30 tumors in total. However, he plans on continuing to serve at his political post, recruiting Lt. Gov. Boyd K. Rutherford (R) to fill in for him when necessary during his chemotherapy treatments. “I’m going to face this challenge with the same energy and determination that I’ve relied on to climb every hill and to overcome ever...
Source: Healthy Living - The Huffington Post - June 23, 2015 Category: Consumer Health News Source Type: news

WHO agency says insecticides lindane and DDT linked to cancer
LONDON (Reuters) - The insecticide lindane, once widely used in agriculture and to treat human lice and scabies, causes cancer and has been specifically linked to non-Hodgkin lymphoma, the World Health Organization said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Gov. Larry Hogan: 'Boyd has my back' during cancer treatment
Maryland Gov. Larry Hogan will lean more heavily on Lt. Gov. Boyd Rutherford as he fights cancer. Hogan, the 59-year-old first-year Republican governor who announced his diagnosis with non-Hodgkin's lymphoma Monday, said he will give more work to Rutherford as he goes through 18 weeks of treatment starting with immediate aggressive chemotherapy. Rutherford will attend meetings Hogan will miss, meetings that are likely to include the Board of Public Works that signs off on state spending. The young… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 22, 2015 Category: Biotechnology Authors: Rick Seltzer Source Type: news

Gov. Larry Hogan: 'Boyd has my back' during cancer treatment
Maryland Gov. Larry Hogan will lean more heavily on Lt. Gov. Boyd Rutherford as he fights cancer. Hogan, the 59-year-old first-year Republican governor who announced his diagnosis with non-Hodgkin's lymphoma Monday, said he will give more work to Rutherford as he goes through 18 weeks of treatment starting with immediate aggressive chemotherapy. Rutherford will attend meetings Hogan will miss, meetings that are likely to include the Board of Public Works that signs off on state spending. The young… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - June 22, 2015 Category: Hospital Management Authors: Rick Seltzer Source Type: news

Maryland Gov. Larry Hogan announces cancer diagnosis
Maryland Gov. Larry Hogan announced Monday he has been diagnosed with non-Hodgkins lymphoma, a form of cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - June 22, 2015 Category: Consumer Health News Source Type: news

Maryland Gov. Larry Hogan has cancer
Maryland Gov. Larry Hogan announced Monday afternoon he has been diagnosed with non-Hodgkin lymphoma. Hogan, a Republican, said at an impromptu news conference that the cancer is very advanced and very aggressive. With his family by his side, Hogan said he would face the challenge with the same energy and determination he has relied on to climb every hill and overcome every obstacle he has faced in his life. Hogan kept a sense of humor in announcing his cancer diagnosis. “The best news is that… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 22, 2015 Category: Biotechnology Authors: Jeff Clabaugh Source Type: news

Maryland Gov. Larry Hogan has cancer
Maryland Gov. Larry Hogan announced Monday afternoon he has been diagnosed with non-Hodgkin lymphoma. Hogan, a Republican, said at an impromptu news conference that the cancer is very advanced and very aggressive. With his family by his side, Hogan said he would face the challenge with the same energy and determination he has relied on to climb every hill and overcome every obstacle he has faced in his life. Hogan kept a sense of humor in announcing his cancer diagnosis. “The best news is that… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - June 22, 2015 Category: Hospital Management Authors: Jeff Clabaugh Source Type: news

Man Pops The Question To High School Sweetheart After Her Last Chemo Session
These high school sweethearts aren't even married yet, and they already know the meaning of "in sickness and in health." Lucas D'Onofrio's girlfriend Tamara was diagnosed with Non-Hodgkin's lymphoma in February. She recently finished her last of six chemotherapy sessions. If that wasn't already cause for celebration, D'Onofrio made the day extra special by planning a surprise proposal for her at Boca Raton Regional Hospital. Courtesy of Lucas D'Onofrio/YouTube He decorated the room with heart balloons, flameless candles, roses and photographs, and then got down on one knee to say the magic words, "Will ...
Source: Healthy Living - The Huffington Post - June 10, 2015 Category: Consumer Health News Source Type: news

SNMMI: PET/CT aids non-Hodgkin's lymphoma patients
PET/CT has the potential to catch a relapse of non-Hodgkin's lymphoma in its (more) (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 10, 2015 Category: Radiology Source Type: news